Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC).
暂无分享，去创建一个
L. Amler | R. Yauch | A. Pandita | V. Ramakrishnan | R. Desai | R. Raja | E. Penuel | A. Peterson | L. Fu | M. Lazarov | S. Mohan | P. Patel | R. Patel | J. Huang | V. Parab | A. Do | J. Zha | M. Lipkind | W. Yu | J. Mango